# Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

> **NCT07079644** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 678 (actual)

## Conditions studied

- Advanced Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab + Relatlimab
- **BIOLOGICAL:** Nivolumab + Ipilimumab
- **BIOLOGICAL:** Immunotherapy monotherapy
- **DRUG:** BRAF/MEK inhibitors

## Key facts

- **NCT ID:** NCT07079644
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-29
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 678 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07079644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07079644, "Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07079644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*